Bistable switch in migration stimulating factor expression: regulation by the concerted signalling of transforming growth factor-β1 and the extracellular matrix

Seth L Schor, Ian R Ellis, Sarah J. Jones, Anne-Marie Woolston, Ana M Schor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Migration stimulating factor (MSF) is an oncofetal motogenic/angiogenic cytokine constitutively expressed by epithelial and stromal cells in fetal and neoplastic tissues. Fibroblasts derived from healthy adult skin do not express MSF but can be induced to do so by treatment with transforming growth factor-ß1 (TGF-ß1). As the bioactivities of both MSF and TGF-ß1 are modulated by the extracellular matrix, we investigated whether the induction of MSF expression by TGF-ß1 is also matrix dependent. We now report that adult fibroblasts are induced to express MSF by a transient treatment with TGF-ß1 (as short as 2 hr) but only when the cells are adherent to a "wound" matrix, such as denatured type I collagen, fibrin or plastic tissue culture dishes. Unexpectedly, this induction of MSF expression persists unabated for the entire subsequent lifespan of the treated cells in the absence of further TGF-ß1 and irrespective of the substratum. Such "activated" MSF expression may, however, be persistently switched off again by a second transient exposure to TGF-ß1 but this time only when the cells are adherent to a "healthy" matrix of native type I collagen. Significantly, the constitutive expression of MSF by fetal and cancer patient fibroblasts could also be persistently switched off by this means. We conclude that TGF-ß1 may both switch on and switch off MSF expression in a manner critically determined by the nature of the matrix substratum and suggest that this may be a possible mechanism underlying the observed dual functionality of TGF-ß1 as both a tumour suppressor and tumour promoter.
Original languageEnglish
Pages (from-to)2024-32
Number of pages9
JournalInternational Journal of Cancer
Volume130
Issue number9
DOIs
Publication statusPublished - 2012

Fingerprint

Transforming Growth Factors
Extracellular Matrix
Fibroblasts
Collagen Type I
Stromal Cells
Fibrin
Carcinogens
Neoplasms
Fetus
Epithelial Cells
Cytokines
Skin
Wounds and Injuries
Therapeutics

Cite this

@article{dc2eac89b0d24743bb9c575e08d902c3,
title = "Bistable switch in migration stimulating factor expression: regulation by the concerted signalling of transforming growth factor-β1 and the extracellular matrix",
abstract = "Migration stimulating factor (MSF) is an oncofetal motogenic/angiogenic cytokine constitutively expressed by epithelial and stromal cells in fetal and neoplastic tissues. Fibroblasts derived from healthy adult skin do not express MSF but can be induced to do so by treatment with transforming growth factor-{\ss}1 (TGF-{\ss}1). As the bioactivities of both MSF and TGF-{\ss}1 are modulated by the extracellular matrix, we investigated whether the induction of MSF expression by TGF-{\ss}1 is also matrix dependent. We now report that adult fibroblasts are induced to express MSF by a transient treatment with TGF-{\ss}1 (as short as 2 hr) but only when the cells are adherent to a {"}wound{"} matrix, such as denatured type I collagen, fibrin or plastic tissue culture dishes. Unexpectedly, this induction of MSF expression persists unabated for the entire subsequent lifespan of the treated cells in the absence of further TGF-{\ss}1 and irrespective of the substratum. Such {"}activated{"} MSF expression may, however, be persistently switched off again by a second transient exposure to TGF-{\ss}1 but this time only when the cells are adherent to a {"}healthy{"} matrix of native type I collagen. Significantly, the constitutive expression of MSF by fetal and cancer patient fibroblasts could also be persistently switched off by this means. We conclude that TGF-{\ss}1 may both switch on and switch off MSF expression in a manner critically determined by the nature of the matrix substratum and suggest that this may be a possible mechanism underlying the observed dual functionality of TGF-{\ss}1 as both a tumour suppressor and tumour promoter.",
author = "Schor, {Seth L} and Ellis, {Ian R} and Jones, {Sarah J.} and Anne-Marie Woolston and Schor, {Ana M}",
note = "Copyright {\circledC} 2011 UICC.",
year = "2012",
doi = "10.1002/ijc.26213",
language = "English",
volume = "130",
pages = "2024--32",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley",
number = "9",

}

TY - JOUR

T1 - Bistable switch in migration stimulating factor expression

T2 - regulation by the concerted signalling of transforming growth factor-β1 and the extracellular matrix

AU - Schor, Seth L

AU - Ellis, Ian R

AU - Jones, Sarah J.

AU - Woolston, Anne-Marie

AU - Schor, Ana M

N1 - Copyright © 2011 UICC.

PY - 2012

Y1 - 2012

N2 - Migration stimulating factor (MSF) is an oncofetal motogenic/angiogenic cytokine constitutively expressed by epithelial and stromal cells in fetal and neoplastic tissues. Fibroblasts derived from healthy adult skin do not express MSF but can be induced to do so by treatment with transforming growth factor-ß1 (TGF-ß1). As the bioactivities of both MSF and TGF-ß1 are modulated by the extracellular matrix, we investigated whether the induction of MSF expression by TGF-ß1 is also matrix dependent. We now report that adult fibroblasts are induced to express MSF by a transient treatment with TGF-ß1 (as short as 2 hr) but only when the cells are adherent to a "wound" matrix, such as denatured type I collagen, fibrin or plastic tissue culture dishes. Unexpectedly, this induction of MSF expression persists unabated for the entire subsequent lifespan of the treated cells in the absence of further TGF-ß1 and irrespective of the substratum. Such "activated" MSF expression may, however, be persistently switched off again by a second transient exposure to TGF-ß1 but this time only when the cells are adherent to a "healthy" matrix of native type I collagen. Significantly, the constitutive expression of MSF by fetal and cancer patient fibroblasts could also be persistently switched off by this means. We conclude that TGF-ß1 may both switch on and switch off MSF expression in a manner critically determined by the nature of the matrix substratum and suggest that this may be a possible mechanism underlying the observed dual functionality of TGF-ß1 as both a tumour suppressor and tumour promoter.

AB - Migration stimulating factor (MSF) is an oncofetal motogenic/angiogenic cytokine constitutively expressed by epithelial and stromal cells in fetal and neoplastic tissues. Fibroblasts derived from healthy adult skin do not express MSF but can be induced to do so by treatment with transforming growth factor-ß1 (TGF-ß1). As the bioactivities of both MSF and TGF-ß1 are modulated by the extracellular matrix, we investigated whether the induction of MSF expression by TGF-ß1 is also matrix dependent. We now report that adult fibroblasts are induced to express MSF by a transient treatment with TGF-ß1 (as short as 2 hr) but only when the cells are adherent to a "wound" matrix, such as denatured type I collagen, fibrin or plastic tissue culture dishes. Unexpectedly, this induction of MSF expression persists unabated for the entire subsequent lifespan of the treated cells in the absence of further TGF-ß1 and irrespective of the substratum. Such "activated" MSF expression may, however, be persistently switched off again by a second transient exposure to TGF-ß1 but this time only when the cells are adherent to a "healthy" matrix of native type I collagen. Significantly, the constitutive expression of MSF by fetal and cancer patient fibroblasts could also be persistently switched off by this means. We conclude that TGF-ß1 may both switch on and switch off MSF expression in a manner critically determined by the nature of the matrix substratum and suggest that this may be a possible mechanism underlying the observed dual functionality of TGF-ß1 as both a tumour suppressor and tumour promoter.

U2 - 10.1002/ijc.26213

DO - 10.1002/ijc.26213

M3 - Article

C2 - 21630266

VL - 130

SP - 2024

EP - 2032

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -